1. 15 Randomized double-blind placebo controlled trial of frontline maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: efficacy assessment in BRCA1/2-wt patients. (13th November 2020) Authors: Rocconi, R; Grosen, E; Ghamande, S; Chan, J; Barve, M; Oh, J; Tewari, D; Morris, P; Stevens, E; Bottsford-Miller, J; Tang, M; Aaron, P; Wallraven, G; Bognar, E; Manning, L; Nemunaitis, J; Slomovitz, B; Herzog, T; Monk, B; Coleman, R Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 3 Page Start: A11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 17 Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. (13th November 2020) Authors: Freyer, G; Pothuri, B; Han, S; Chase, D; Monk, B; Heitz, F; Burger, R; Gaba, L; Van Le, L; Guerra, E; Bender, D; Korach, J; Cloven, N; Churruca, C; Follana, P; DiSilvestro, P; Baurain, JF; Jardon, K; Pisano, C; Peen, U Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 3 Page Start: A12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 263TiPATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer. (24th November 2019) Authors: Fujiwara, K; Chou, H-H; Kim, J-W; Tan, D S; Tamura, K; Katsumata, N; Harano, K; Hasegawa, K; Hume, S; Jones, E; Goble, S; Sullivan, L; Shih, D; Coleman, R L; McNeish, I; Monk, B; Kristeleit, R Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 265TiPKEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer. (24th November 2019) Authors: Fujiwara, K; Shapira-Frommer, R; Alexandre, J; Monk, B; Fehm, T; Colombo, N; Caceres, M V; Hasegawa, K; Dubot, C; Li, J J; Stein, K; Keefe, S M; Tewari, K Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 358 Phase 3 trial of tumor treating fields concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: ENGOT-ov50/GOG-329/INNOVATE-3. (13th November 2020) Authors: Vergote, I; Salutari, V; Cibula, D; Korach, J; Samartzis, EP; Sehouli, J; Fossati, R; Martin, AG; Tsibulak, I; Slomovitz, B; Coleman, R; Monk, B; Thaker, P; O'Malley, D Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 3 Page Start: A147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 372 Safety and activity of the anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. (13th November 2020) Authors: Santin, A; Vergote, I; Martín, A; Moore, K; Oaknin, A; Romero, I; Diab, S; Copeland, LJ; Monk, B; Coleman, R; Herzog, TJ; Siegel, J; Walter, A; Childs, BH; Elbi, C; Bulat, I Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 3 Page Start: A154 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 393 Keynote-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. (18th September 2019) Authors: Tewari, K; Caceres, MV; Alexandre, J; Monk, B; Fehm, T; Colombo, N; Hasegawa, K; Dubot, C; Li, JJ; Stein, K; Keefe, S; Shapira-Frommer, R Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 3 Page Start: A162 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P154 Tumor treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: phase 3 INNOVATE/ENGOT-ov50 study. (1st November 2019) Authors: Vergote, I; Copeland, L; Monk, B; Coleman, R; Cibula, D; Sehouli, J; Samartzis, EP; Madry, R; González Martin, A; Korach, J; Salutari, V; Witteveen, PO; O'Malley, D Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Radiotherapy instead of inguinofemoral lymphadenectomy in vulvar cancer patients with a metastatic sentinel node: results of GROINSS-V II. (1st November 2019) Authors: Oonk, MHM; Slomovitz, B; Baldwin, P; van Doorn, H; van der Velden, J; de Hullu, J; Slangen, B; Gaarenstroom, K; Vergote, I; Brannstrom, M; van Dorst, E; van Driel, W; Hermans, R; Nunns, D; Widschwendter, M; Nugent, D; Holland, C; DiSilvestro, P; Sharma, A; Mannel, R Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Severe cutaneous reactions to alternative remedies. Issue 6548 (13th September 1986) Authors: Monk, B Journal: BMJ Issue: Volume 293:Issue 6548(1986) Page Start: 665 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗